Endogenous Mitochondria Resistance to Acute Kidney Injury

描述（由申请人提供）： 急性肾损伤（阿基）发生在所有住院患者的5-7%中，最近的证据表明，即使是肾功能的微小变化也与死亡风险增加有关。在ICU中，阿基与50%的死亡率相关，即使接受透析治疗，这一统计数据也没有改变。事实上，急性肾衰竭试验网络研究（VA和NIH联合申办的透析给药研究）显示，在比较透析给药时，死亡率统计没有变化。显然，迫切需要新的方法来解决这种危及生命的疾病。鉴于VA人口正在老龄化，容易患糖尿病和高血压，阿基是这一群体的主要健康问题。在完成这项VA Merit审查后，肾脏领域的研究者将有新的小分子药物发现目标，这些药物将改善与阿基相关的死亡率。

DESCRIPTION (provided by applicant): Acute kidney injury (AKI) occurs in 5-7% of all hospital admissions and recent evidence has shown that even minor changes in renal function are associated with increased risk of death. In the ICU, AKI is associated with 50% mortality, a statistic which has not changed even with dialysis therapy. In fact the Acute Renal Failure Trial Network study, a combined VA and NIH sponsored dialysis dosing study, showed no change in mortality statistics when comparing dialysis dosing. Clearly new approaches are urgently needed to address this life-threatening disease. Given the fact that the VA population is aging, prone to diabetes and hypertension, AKI is a major health problem in this group. Upon completion of this VA Merit Review, investigators in the renal community will have new targets for small molecular drug discovery that should ameliorate the mortality associated with AKI.